BioMarin sales and marketing update

BioMarin disclosed the price of newly launched Vimizim elosulfase alfa, which FDA approved earlier in February to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). The wholesale acquisition cost of the recombinant human N-acetylgalactosamine-6-sulfatase is $1,068 for a 5 mg vial. The recommended dose is 2 mg/kg once weekly. Including "discounts and expected compliance," the company said this translates to an average annual cost of about $380,000 for a typical 22.5 kg patient. ...